Hematopoiesis is coordinated by a complex regulatory network of transcription factors and among them PU.1 (Spi1, Sfpi1) represents a key molecule. This review summarizes the indispensable requirement of PU.1 during hematopoietic cell fate decisions and how the function of PU.1 can be modulated by protein-protein interactions with additional factors. The mutual negative regulation between PU.1 and GATA-1 is detailed within the context of normal and leukemogenic hematopoiesis and the concept of 'differentiation therapy' to restore normal cellular differentiation of leukemic cells is discussed.
PU.1 and its role in hematopoiesis
Hematopoiesis is a highly orchestrated multi-step process regulated by transcription factors that involves the proliferation, differentiation and maturation of a very small population of selfrenewing, pluripotent hematopoietic stem cells into various specialized and distinct blood cell types. During this process, cellular specification is initiated by primary lineage determinants, such as the transcription factor PU.1. At sub-threshold levels, primary determinants can 'transcriptionally prime' multipotential progenitors to establish a low-level expression of a mixed lineage pattern of gene expression. [1] [2] [3] Upon reaching a critical threshold of activity, the primary determinants will differentiate the multi-potential progenitors along a particular cell-fate and this commitment is regulated by secondary regulators (transcription factors that cooperate or antagonize with primary determinants) which function to 'lock in' the decision by repressing the alternate lineage and aide in promoting the uni-lineage choice. 2, 4 PU.1 is encoded by the Sfpi1 (Spi-1) gene and produces a protein consisting of 272 amino acids (predicted MW of 31 kDa), and is related to the Spi-B and Spi-C Ets-family factors (both sharing approximately 40% amino acid homology). PU.1 contains various distinct functional domains namely an Ets domain that shows a winged helix-turn-helix domain and recognizes DNA sequence harboring the core GGAA motif. 5 Additional domains include an N-terminal acidic domain and a glutamine-rich domain, both involved in transcriptional activation, as well as a PEST domain involved in protein-protein interactions. PU.1 protein can be modified post-translationally by phosporylation at serines 41 (N-terminal acidic domain) and 142 and 148 (PEST domain), which results in augmented activity.
The PU.1 protein can physically interact with a variety of regulatory factors including (i) general transcription factors (TFIID, TBP), (ii) early hematopoietic transcription factors (GATA-2 and Runx-1), (iii) erythroid factor (GATA-1) and (iv) non-erythroid factors (C/EBPa, C/EBPb, IRF4/8 and c-Jun). Interestingly, such protein-protein complexes can modify PU.1 overall transcriptional activity. As such, these interactions can be employed to modulate PU.1-dependent cell fate decisions and provides context-dependent decision to be dictated based on the specific nature of PU.1 interactions with other proteins.
PU.1 is key differentiation regulator that, in concert with its transcriptional partners, can modulate the expression of at least 3000 genes expressed in hematopoietic cells, 2, 6 including known cell-surface proteins (CD11b, CD16, CD18 and CD64), cytokines and their respective receptors (G-CSF, GM-CSF and M-CSF) and many other gene targets expressed during myelopoiesis and hematopoietic stem cells (HSC) homing. 7 Recent ChIP-Chip approaches using tiled promoter arrays have identified 41000 direct target genes of PU.1 within terminal macrophages (murine RAW264 cell line) locating the majority of PU.1 occupied regions within the proximal core promoter region. 8 Several examples document that some PU.1 binding sites are located close to the transcriptional start of TATA-less genes (for example, M-CSFR and FcgR1b) and have an important role in gene activation by recruiting the transcriptional machinery. 4, 9 These data are supported by experimental exchange of the PU.1 cis-binding site to that of a TATA box leading to activation of myeloid promoters by mechanism involving direct interaction with TBP and with a set of TATAassociated factors.
10 Interestingly, PU.1 binding sites are often accompanied by other DNA cis-elements of known transcriptional hematopoietic co-regulators (for example, Sp1, IRF, RUNX-1 and C/EBP) indicating gene regulation by a combinatorial manner consisting of various transcription factors. 9, [11] [12] [13] [14] [15] Examples of such combinatorial regulation include PU.1 in conjunction with Sp1 to regulate the c-fes gene 16 or with IRF-4 during direct activation of immunoglobin light and heavy chain genes. 17, 18 The nature of the PU.1 protein complexes formed at the regulatory sites of target genes dictates the extent to which genes are transcribed and thus altering the composition of the PU.1 protein complex can be used to regulate lineage-specific gene expression of PU.1 target genes.
PU.1 mRNA and protein expression begins within HSC and is attenuated in common lymphoid and myeloid progenitors and also within subsequent daughter cells. PU.1 is expressed in mature monocytes, granulocytes, B and NK cells yet absent in T cells, reticulocytes and megakaryocytes. 19, 20 The PU.1 gene itself is transcriptionally regulated by several mechanisms. The proximal promoter of Spi1 contains binding sites for PU.1 indicating a self autonomous regulatory mechanism of gene expression 21 as well as binding sites for Oct-1, Sp1, GATA-1 and Spi-B, which likely mediate initial regulation (activation or repression) of PU.1 during hematopoietic development. Despite the presence of numerous cis-regulatory elements, the proximal Spi1 promoter alone is insufficient to drive PU.1 expression in a correct tissue-specific manner unless the distal regulatory enhancer (URE, upstream regulatory element) is also present. 22, 23 The distal enhancer is located within a DNAse I hypersensitivity site located 14 and 17 kb upstream of the PU.1 transcription start site in mouse and humans, respectively. 23 Although the URE is required for optimal PU.1 expression, its molecular regulation of transcription is complex. Deletion of URE in the mouse has a detrimental effect on the PU.1 protein level reducing it to 20% of normal levels. 24, 25 Various transcription factors can bind to the URE including PU.1 itself, Elf1, FLI-1, Runx-1 and C/EBP. 11, 23, 26, 27 The URE regulates transcription of both sense as well as antisense non-coding transcripts and this provides an additional layer of modifying PU.1 activity via the regulation of protein translation. 28 The expression of PU.1 is regulated post-transcriptionally as the 3 0 untranslated region of PU.1 mRNA can be inhibited by the microRNA miR-155, 29 which is generated from a precursor primiR-155 encoded by the BIC gene. 30 miR-155 can negatively regulate an array of approximately 400 target mRNAs with diverse function in hematopoietic progenitors, B and T-cells and also in precursors of macrophages and granulocytes. 29, 31 Previous studies have shown that miR-155-deficient mice display defects in both B and T cell-mediated immune response 31 and reduced numbers of B-cell germinal centers. 30 The requirement of PU.1 during hematopoiesis has been addressed by various experimental approaches, however, the most definitive are those involving highly specific mouse models produced by genetic manipulation at the level of embryonic stem cells. Deletion of PU.1 in mice results in a relatively late embryonic lethality (around E17.5). 32 PU.1 À/À mice have a reduced pool of HSC and progenitors [33] [34] [35] leading to the loss of mature macrophages, neutrophils, B-cells, T-cells and mast cells 32, 36, 37 and to the mild defect of erythropoiesis. 33 Interestingly, PU.1 null hematopoietic progenitors express diminished levels of the myeloid growth-factor receptors (G, GM, M) yet can be expanded in vitro upon addition of the IL-3 cytokine indicating that their growth survival can be regulated in a PU.1-independent fashion. 36, 38, 39 Conditional deletion of the PU.1 gene in adult bone marrow progenitors showed its requirement for both monocyte and lymphoid progeny whereas granulocyticlike cells were increased indicating that PU.1 may inhibit adult in vivo granulopoiesis at latter stages of development. 34, 40 Similarly, PU.1 has only a minor function in advanced differentiation states of B cells 25, 34, 35, [41] [42] [43] and is not required in mature T cells. [44] [45] [46] Collectively the above-mentioned facts reveal an important and crucial role of PU.1 as a primary transcriptional determinant of hematopoietic cell fate with current evidence showing its substantial role in the cell fate control of HSC and progenitor populations rather than the maturation of terminally differentiated cells.
PU.1 and GATA-1 interact during early hematopoietic cell decisions
Work from laboratories of A. Skoultchi, D. Tenen and T. Graf showed that PU.1 and GATA-1 proteins physically interact with each other within hematopoietic cells. It was in subsequent studies that elucidated how this process is accomplished and, more importantly, the molecular consequences of this protein-protein interaction during normal and pathological hematopoiesis. [47] [48] [49] The initial findings that GATA-1 and PU.1 proteins are components of a minimal gene regulatory network regulating the erythroid cell fate choice came from their unnatural co-expression in erythroleukemic cells (MEL cells) of mice that harbor the friend virus integration within the URE of the Spi-1 gene. This viral integration caused the aberrant and constitutive expression of PU.1 throughout the erythroid compartment resulting in the erythroleukemic pathology. 50 These findings were subsequently corroborated by experiments with PU.1-overexpressing transgenic mice that develop erythroleukemias at a high rate. 51 MEL cells can be cultured in vitro and by treatment with certain chemical inducers (DMSO, HMBA) can accomplish the process of terminal erythroid differentiation followed by a proliferation block. 52, 53 During this differentiation process, PU.1 expression declines whereas GATA-1 remains expressed. Similar to the chemical inducers, expression of exogenous GATA-1 can induce MEL differentiation along the erythroid lineage. 54 Conversely, the transgenic overexpression of PU.1 in MEL cells can block the GATA-1-mediated differentiation of MEL cells and induces an oncogenic phenotype. 55 Collectively, these observations show that the dysregulation of PU.1 expression is responsible for the oncogenic properties of MEL cells. Despite these findings, it is curious to note that PU.1 is mainly pro-differentiation factor in monocytes, granulocytes and B-lymphocytes and thus to explain its possible prooncogenic function within erythroid progenitors required further detailed structural analyses.
The ability of PU.1 and GATA-1 proteins to physically interact was first shown using in vitro GST-pull down assay and by coimmunoprecipitation assays using overexpressed proteins within mammalian cell lines. 47 Using various sets of protein-deletion mutants (employed in the abovementioned assays) it was shown that PU.1 directly interacts with the zinc-finger region of GATA-1 through its C-terminal DNA-binding domain. [47] [48] [49] Homologs of GATA-1 (GATA-2 and GATA-3) and PU.1 (SPI-B) can also interact with each other, however, display significantly lower affinities. 47 In reporter assays using MEL, as well as non-hematopoietic cells, PU.1 efficiently blocks GATA-1 transactivation of plasmid constructs and this effect is dependent on the presence of both DNA-binding as well as the transactivation domain of PU.1. 47 As PU.1 can block erythroid MEL differentiation 55 and GATA-1 stimulates erythroid differentiation 54 it seems quite possible that the stoichiometry between PU.1 and GATA-1 determines whether MEL cells remain arrested in an erythroleukemic state or are able to be withdrawn from this block and consequentially induce the gene expression program associated with erythroid differentiation. The mechanism of such stoichiometry can operate in the absence of DNA-binding sites and therefore the transcription factors can either mutually block each other's accession to DNA 56 or can coexist on DNA and block each other's transactivation by protein-protein interactions within chromatin. 49, 57 Initially it was thought that PU.1 prevents binding of GATA-1 to DNA as shown by electrophoretic mobility shift assays. 56 However, by using DNase-I footprinting such inhibition was PU.1 and GATA-1 in leukemia differentiation P Burda et al observed at a non-physiological molar ratio (20:1) whereas at a 1:1 ratio PU.1 actually altered the GATA-1-generated footprint near the GATA-1-binding site thereby arguing for the possibility that both PU.1 and GATA-1 coexists on DNA. 57 The GATA-1 reporter construct was transfected into U2OS cells, a human osteosarcoma cell line, and in this in vivo assay it clearly responded positively to GATA-1 and negatively following the addition of PU.1. 57 Chromatin immunoprecipitation studies showed the co-occupancy of both PU.1 and GATA-1 proteins to DNA 57 and that this co-occupancy was dependent on the presence of both a GATA-1 cis-binding site and the Ets domain on the PU.1 protein. Interestingly, the N-terminal portion of PU.1 does not affect the occupancy of PU.1 and GATA-1 on its DNA-binding site 57 yet is required to bind with the retinoblastoma protein (pRb) for repression of GATA-1. 57 Conversely, PU.1 is able to repress GATA-1-mediated transcription even when the C-terminal zinc-finger region of GATA-1 was replaced by GAL4 DNA-binding domain, which does not interact with PU.1. 57 Data of several laboratories collectively show that PU.1 inhibits GATA-1 on DNA, 57, 58 although effects of PU.1-binding GATA-1 outside DNA cannot be excluded.
Despite these biochemical studies, the question still remained as to how exactly is the repressive activity of PU.1 being generated and executed. Above-mentioned experiments identified that the acidic subdomain of PU.1 binds the C-pocket of pRb and that this interaction is required for repression of GATA-1-mediated erythroid differentiation. 57 The most obvious question arose as to how and with whom pRb mediates the repressive activities of PU.1? Detailed analyses of both endogenous and transgenic integrated GATA-1 DNA-binding sites revealed that PU.1 represses GATA-1 by recruiting pRb, Suv39h and HP1a leading to local histone H3K9 methylation. 58 This multi-protein complex is detected within close proximity of GATA-1-binding sites of important erythroid genes (for example, Hbb-b1 and HS2, HS3 of locus control region, Hbb-a2, Alase, Zfpm1, Nfe2 and Eklf) and its formation requires the presence of GATA-1 protein. 58 Derepression of GATA-1 target genes can, in turn, be efficiently achieved following the inversion of H3K9 methylation near repressed genes to those of H3K9 acetylation, a mark of transcriptionally active chromatin. Such exchange in the modification of the histone proteins can be induced by both activation of endogenous GATA-1 or inhibition of PU.1 expression in MEL cells. 58 On the basis of these observations (as depicted in Figure 1 , left panel), it is very likely that PU.1 uses similar mechanism (as identified in MEL cells) to repress the erythroid transcriptional program during normal myeloid/ lymphoid differentiation.
The mechanism of mutual GATA-1 and PU.1 repression has been examined and corroborated in several different cellular systems. In chicken myeloblasts GATA-1 downregulates the myeloid marker MHCIIg without altering PU.1 levels. 49 Validating the earlier findings (as described above), mutation of GATA-1 C-terminal sequence could inhibit GATA-1-mediated repression of PU.1 in luciferase reporter assays and furthermore, this same region is sufficient for the activation of GATA-1-mediated transcription. 49 Although the cross-antagonistic model between PU.1 and GATA-1 is simplistic in its nature, the presence of additional binding partners for both proteins create a far more complex regulatory network that now includes additional inputs. For example, c-Jun, a bZIP transcription factor, which is part of the AP-1 transcription factor complex, functions as a critical coactivator of PU.1 transactivation of various myeloid promoters including the M-CSF receptor. 59 Repression of the M-CSF receptor can be caused by GATA-1 whereby it displaces c-Jun from PU.1 leading to the reduction of PU.1 activity. 48 This mechanism is supported by abilities of GATA-1 and c-Jun to specifically bind to the Ets domain of PU.1 and therefore they can both compete for their respective interaction with the DNAbinding domain of PU.1. 48 Collectively these, and the aforementioned studies, strongly support the molecular model that mutually interacting PU.1 and GATA-1 proteins represent an integral component in the specification of multi-potential hematopoietic cells along the myeloid and erythroid lineages respectively and, furthermore, functions as a minimal cross-antagonistic gene regulatory network that dictates the development of early multi-potential progenitors to activate its own lineage-specific gene expression programs and concomitantly repress alternate-lineage gene expression profiles. Recent genetic studies have validated the proposed regulatory model by using GATA-1 and PU.1 endogenous reporters in mouse. 60 GATA-1 and PU.1 expression was PU.1 and GATA-1 in leukemia differentiation P Burda et al detected within multi-potential progenitors with the GATA-1-positive population displaying a restricted myelo-erythroid potential lacking the potential to produce lymphocytes. Alternately, PU.1-positive multi-potential progenitors displayed granulocyte/monocyte/lymphoid-restricted progenitor activity lacking the developmental potential for megakaryocyte/ erythroid differentiation.
It is important to note that the combinatorial effect of PU.1 and GATA factors (not only GATA-1, but also GATA-2 and GATA-3) represent highly cell context-dependent mechanism of cell fate specification. For example, despite their inclination for cross-antagonism, during eosinophil and mast cell development the GATA and PU.1 factors actually synergize together to promote differentiation. 36, 61 Additional factors that interact with GATA-1 or PU.1 can also modulate the cell-dependent specificity of their activities. The nuclear factor FOG-1 (ZFPM1) is a coactivator of GATA-1 [62] [63] [64] and is coexpressed with GATA-1 during embryonic development within erythroid and megakaryocytic cells.
65 Surprisingly, in eosinophil and mast cells, FOG-1 can antagonize GATA-1 activity thereby functioning as a corepressor within this cellular-dependent context. 62, 66 The widely explored model of cell fate decisions during hematopoietic stem and progenitor development is based on the cross-antagonistic relationship between the PU.1 and GATA-1 transcription factors. However, once multi-potential progenitors differentiate into latter precursor stages such as monocyte/ granulocyte development, GATA-1 is no longer expressed and the process of cell specification depends on PU.1 and another primary lineage determinant, CEBPa. 67 The cellular commitment into the monocyte or granulocyte lineage relies on the engagement of counter-antagonistic secondary lineage determinants, Gfi-1, Egr-1/2 and Nab-2, in the process of activation and repression of macrophage and neutrophil genes, respectively. 2, 4 Striking similarities are observed in the regulatory circuit described for the development and subsequent lineage differentiation from megakaryocyte/erythroid progenitors. The generation of the bipotential megakaryocyte/erythroid progenitors progenitor arises from the loss of PU.1 with the ensuing process of erythrocytic versus megakaryocytic commitment dependent upon the EKLF and Fli-1 transcription factors, respectively. 68 Although the precise mechanism of how EKLF and Fli-1 can direct lineage commitment remains to be determined, recent studies have shown the EKLF-mediated repression of megakaryopoiesis by the inhibition of Fli-1 recruitment to megakaryocytic-specific promoters as well as to its own promoter. 69 Based on these observations, mutual cross-antagonism between transcription factors is a common and re-occurring mechanism in regulating cell fate choices during hematopoiesis.
PU.1 can regulate cell fate choice not only by (i) antagonistic or synergistic interplay with other primary determinants (GATA-1, C/EBPa), (ii) interaction with secondary lineage determinants but also by (iii) concentrations of its own expression where substantial evidence strongly suggests that higher levels of PU.1 preferentially promotes myeloid development whereas lower levels is required for efficient B-cell development. [70] [71] [72] [73] Moreover, lowering levels of PU.1 within multi-potential progenitors can enhance B lymphopoiesis 74 establishing a role for PU.1 concentrations in the regulation of myeloid versus B lymphocyte cell fate choice.
PU.1 and GATA-1 are often described as 'master regulators' largely based on their hierarchical position during hematopoiesis as well as their ability to induce cellular trans-differentiation when expressed transgenically. The effects of ectopic expression of PU.1 and C/EBP was studied in committed T-cells and revealed that C/EBPa/b reprogrammed these cells into inflammatory macrophages, whereas PU.1 generated myeloid dendritic-like cells. 75 Interestingly, the mechanism of the T-cell reprogramming by PU.1 and C/EBP requires downregulation of the primary T-cell determinants Notch1 and GATA-3. 75 Recent studies have shown that even the simple ectopic expression of both PU.1 and C/EBPa within mesenchymal stem cell-derived fibroblasts is sufficient to activate the myeloid program resulting in an induced macrophage-like phenotype capable of phagocytosis. 76 Finally, enforced expression of GATA-1 leads to reprogramming of myeloblasts and CD34
þ bone marrow cells into eosinophils, 77, 78 whereas within mouse granulocyte-monocyte progenitors ectopic GATA-1 can reprogram these cells to adopt erythroid, eosinophilic or basophile-like properties. 79 The above-described observations show that PU.1 and GATA-1 act as 'the motors for reprogramming' and this correlation could be very useful with regard to the application of 'differentiation therapy' whereby re-establishing the correct expression of PU.1 and or GATA-1 within immature leukemic cells, or those attempting to mature into an unwanted lineage should reprogram and differentiate these cells back into their respective cellular lineage.
GATA-1 and PU.1 levels are determinants of leukemogenesis
Several key studies have shown that dysregulation of either PU.1 or GATA-1 activity can contribute to leukemogenesis. 24, 25, 80, 81, 82 Targeted disruption of the URE in mice significantly reduces PU.1 expression and results in the development of acute myeloid leukemia with frequent cytogenetic aberrations. 24 The URE structure is dynamically regulated by chromatin loops associated with the chromatin remodeling regulator SATB1 bound directly to the URE. SATB1 binds to special AT-rich sequences and its expression appears to be a positive regulator of PU.1 expression requiring an intact URE. 83 Mice deleted of the Satb1 gene showed lower levels of PU.1 in progenitor cells but not in the terminally differentiated progeny indicating that Satb1 may cooperate in early stages of myeloid development. 83 Satb1 À/À mice, unlike URE À/À mutants, do not develop myeloid leukemia. However, it should be noted that Satb1 À/À mice die prematurely (early postnatal) and the limited life-span may not be sufficient for any myeloid leukemias to develop. Interestingly, a single nucleotide polymorphism within the URE has been identified, which significantly diminishes binding of SATB1. The single nucleotide polymorphism is frequently associated with poor prognosis of human leukemias 83 and strongly suggests that the altered URE enhancer activity is coupled with reduced PU.1 levels within developing myeloid progenitors thereby contributing to the pathogenesis of human myeloid leukemias.
Regulation of PU.1 at the post-transcriptional level by miR-155 provides an additional example of how dysregulation of PU.1 expression could contribute to human leukemo/lymphomagenesis. Elevated levels of miR-155 have been found in myeloproliferative and lymphoproliferative diseases such as acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and Hodgkin's lymphoma. 30, [84] [85] [86] As PU.1 mRNA is a direct target of miRNA-155 it is likely that this dysregulation of PU.1 expression, among other crucial gene targets, contributes to the development of certain hematological malignancies.
Mutations of the GATA-1 gene can generate a truncated protein, which contributes to development of transient myeloproliferative disorder and acute megakaryoblastic leukemia in patients with Down's syndrome. 80, 81 Similarly, the knockdown PU.1 and GATA-1 in leukemia differentiation P Burda et al of GATA-1 expression to approximately 5% of its wild-type level causes high incidence of erythroleukemia in mice. 87 Therefore the manipulation of either PU.1 or GATA-1 levels produces cellular phenotypic features of blocked differentiation and unlimited proliferation potential. Collectively, the molecular interaction between GATA-1 and PU.1 occurs during early lineage commitment of multi-potential progenitors and enable rapid cell fate choices between the development of leukocytes or red cells from a common progenitor. Once this decision is made within erythroid cells, the PU.1 gene becomes repressed and conversely in developing leukocytes the production of GATA-1 is inhibited. Perturbations of this process can result in a leukemic blockade.
As mentioned earlier, both PU.1 and GATA-1 proteins are coexpressed in MEL cells where the individual levels of each transcription factor are sufficient to initiate specific changes of chromatin structure within their respective target genes. As such, the promiscuous activity of PU.1 blocks erythroid differentiation at a proerythroblast stage (Figure 2 ). This developmental arrest is relieved by either PU.1 inhibition or increasing GATA-1 activity culminating in the restoration of normal erythroid differentiation. 54, 58 Reciprocally, inhibition of GATA-1 or increased PU.1 activity results in the non-erythroid differentiation of the MEL proerythroblasts into cell cycle arrested cells with myelolymphoid characteristics 6 ( Figure 2 ). Using this cellular system, recent studies have identified key target genes that are directly regulated as a consequence of manipulating the stoichiometric balance between PU.1 and GATA-1. Gene expression profiling combined with chromatin immunoprecipitation identified two key hematopoietic transcription factors, C/EBPa and Cbfb, that are direct targets for both PU.1-mediated activation and GATA-1-mediated repression. 6 Interestingly, both C/EBPa and CBFB are required for normal myeloid development and mutations in either can give rise to leukemia. [88] [89] [90] The dynamic relationship between PU.1 and GATA-1 during both the leukemic state of MEL cells and also upon MEL differentiation can be described in the following putative steps: at myeloid genes such as C/EBPa, PU.1 binds directly to DNA but its transactivation is antagonized by GATA-1 binding directly to PU.1 molecules on DNA. Activation of exogenous PU.1 combined with stable levels of GATA-1 create an excess of available PU.1, which is not paired by available GATA-1, thus altering the stoichemistry between these two proteins resulting in PU.1-mediated gene activation associated with acquisition of active chromatin mark Acetyl H3K9 near the PU.1-binding sites (Figure 1, right panels) . The reciprocal mechanism is shown for erythroid-specific genes such as Nfe2. These findings collectively show that manipulating the relative expression of transcription factor levels (for example, inhibition of GATA-1 or activation of PU.1 (or vice versa), in erythroleukemias may represent an efficient tool for inducing, and rescuing, leukemic blasts cells into a differentiated cell state. 6, 91 In summary, regulation of both PU.1 and GATA-1 expression levels are crucial for the correct cell fate determination of multipotential progenitors and that inappropriate regulation of these primary determinants can cause a block of cell differentiation and expansion of a clonal population of leukemic cells. The developmental block seems to occur at the differentiation stage where primary determinants are beginning to specify a cell fate lineage by activating key target transcription factors. This is clearly exemplified within MEL cells where PU.1 inhibits GATA-1-mediated transactivation of its target genes such as Fog1 and Nfe2, and concomitantly GATA-1 inhibits, albeit incompletely, PU.1-mediated transactivation of its targets being additional primary myeloid lineage determinants such as C/EBPa and CBFB. 6 It is very important to note that most of the PU.1 target genes are repressed in MEL cells and thus targeting of C/EBPa and CBFB by PU.1 likely represents crucial PU.1-dependent determinants and reflects an intermediate developmental process of the myelo-lymphoid cell fate. Conversely, Nfe2 and Fog1 are two very important GATA-1 direct targets and represent early GATA-1-dependent determinants. Understanding such molecular mechanisms can become useful tools for understanding of both normal hematopoiesis as well as the pathogenesis of human leukemias.
The concept of differentiation therapy by modulating chromatin structure with GATA-1 and PU.1
The generation and establishment of a leukemic blockade is associated with extensive gene-specific changes in chromatin structure that represents both a genetic marker of a dysregulated cell as well as a tool for manipulating the gene expression to rescue the expression of a gene program back into a normal state. Hematopoietic transcription factors can initiate chromatin changes near their binding sites by recruiting chromatin modification enzymes including histone acetyltransferases and histone deacetylases (HDACs). The chromatin modifiers are not specific to any one transcription factor as both GATA-1 and PU.1 can directly interact with either the histone acetyltransferase CBP (CREB-binding protein) resulting in enhanced gene activation 92, 93 or with HDACs, which enables efficient gene repression and is often accompanied by histone H3K9 methylation. 94 Surprisingly, inhibition of the H3K9-methylating enzymes Suv39h or H3K9-binding protein HP1a within MEL cells does not lead to derepression of GATA-1 target genes unless PU.1 itself is present. 58 However, changing the stoichiometry between PU.1 and GATA-1 during induced erythroid differentiation of MEL cells have been shown to facilitate an exchange between modified (H3K9 methylated) H3 with unmodified H3.3 near derepressed GATA-1 DNA target genes. 58 This shows the complexity in attempting to alter the expression of chromatin modifiers to 'reset or reprogram' any gene regulatory network with current research intensely PU.1 and GATA-1 in leukemia differentiation P Burda et al focused on how specific histone marks can be efficiently and rapidly reversed. Such mechanisms involves enzymatic cleavage of modified histone residue, example includes HDACs and histone demethylases. 95 Demethylase domain proteins are able to target active mark H3K4Me3 (often associated with recruitment of RNA polymerase II) to repress transcription 95 or to demethylate inactive mark H3K9 to activate transcription. 96 There are many ongoing clinical trials that use globaloperating inhibitors of histone and DNA modifications to manipulate leukemic gene expression profiles. Histone deacetylase inhibitors (iHDAC) are widely studied anticancer agents, which not only inhibit tumor growth and survival but reinitiate differentiation and or induce apoptosis. 97 The molecular mechanism of why tumor cells are more sensitive and susceptible to iHDAC is not fully understood yet likely includes differences in transcriptional regulation of genes involved in cell cycle, apoptosis or survival. Notably, in the human breast carcinoma cell line MA-11 some iHDAC can cause cell cycle arrest in G1 phase mediated through the induction of cyclindependent kinase p21, 98 whereas other inhibitors (trichostatin) induce a delay at the G(2)/M transition, chromosome missegregation and multi-nucleation and thereby induce cell death by promoting exit from aberrant mitosis without spindle checkpoint. Azacitidine is a member of drugs known as DNAdemethylating agents and its anticancer effects are believed to be twofold by its ability to demethylate DNA as well as prevent the methylation of DNA. By demethylation mechanism, transcription of tumor suppressor genes can be restored, resulting in recovery of the cell cycle control. Valproic acid also displays iHDAC properties that can induce the in vitro differentiation of transformed hematopoietic progenitors and leukemic blasts in acute myeloid leukemia patients. 99 Despite the current drug regimes, the effects of HDAC inhibitors and DNA methyltransferase inhibitors in leukemic patients are not cell specific, do not lead to significant improvement in overall survival and therefore still remain as an experimental approach. In this regard it seems that an alternate, and more effective approach for the clinical applications of 'differentiation therapy', would be to specifically manipulate the expression and-or activities of targeted transcription factor(s) rather than the use of global inhibitors of chromatin modification enzymes, which have low gene specificity.
Targeting transcription factor proteins and miRNA molecules with the aim of restoring their normal functional activity has significant potential in the 'differentiation therapy' of leukemias. Modification of gene-specific transcriptional activities within tumor cells was first used using all-trans-retinoic acid (ATRA), the acid form of vitamin A, by Zhen Yi Wang of Shanghai Medical School in the late 1980s in the treatment of acute promyelocytic leukemia (APL). 100 APL represent an acute myeloid leukemia that is characterized by chromosomal translocations involving the transfer of sequence-encoding retinoic acid receptor a (RARa) and is unique from other acute myeloid leukemia subtypes in its specific responsiveness to ATRA therapy. By inhibiting HDACs and DNA methyltransferase activities, pharmacological doses of ATRA can modify the chromatin structure as well as the DNA methylation pattern at specific DNA-binding sites on target genes for retinoic acid resulting in terminal granulocytic differentiation of APL. [101] [102] [103] [104] [105] [106] ATRA exert its effects by modulation of gene expression by two distinct classes of nuclear receptors: retinoic acid receptors (RAR) and retinoid X receptors. ATRA binds with high affinity to RARs, but not to retinoid X receptors. Binding of retinoids to the receptor dimer complexes induces a conformational change that displaces the existing corepressor proteins and recruits coactivators, thus facilitating initiation of transcription. 107 Conditional expression of PML-RARa (protein encoded by the t(15;17) translocation) in HT93 acute promyelocytic cells suppressed PU.1 expression, whereas treatment of APL cell lines and primary APL leukocytes with ATRA was capable of restoring PU.1 expression and induced neutrophil differentiation. 108 These observations strongly indicate that ATRA treatment was capable of inducing differentiation of the developmentally arrested leukemic cells through re-establishing the underlying gene regulatory network.
The literature discussed in this review strongly supports the concept that dysregulation of transcription factors is a key contributing factor in the pathogenesis of myeloid leukemias. A greater understanding of the gene regulatory network that orchestrates normal, as well as leukemogenic differentiation will be of fundamental importance in achieving critical goals for the clinical application of these regulatory factors in myelodysplasia and myeloid leukemias. After all, it is not impossible to imagine that under certain conditions, targeting transcription factors with the aim of restoring their normal functional activity would result in the production of mature cells that would restore their normal function within leukocytes and or red blood cells.
